This study compared the oncologic outcomes of treatment with oral adjuvant chemotherapy regimens, UFT/LV or capecitabine. Retrospectively, 258 patients were reviewed. 3-year RFS and OS were not significantly difference. The outcomes also did not differ regardless of whether patients completed the scheduled total treatment dose. Treatment decisions can thus focus on other issues such as cost, convenience, and adverse effects. Introduction: Although several major trials of treatment for stage III colon cancer have been reported, no study has compared oral adjuvant chemotherapy regimens using tegafureuracil in combination with leucovorin (UFT/LV) and capecitabine (CAPE) alone. This study compared the oncologic outcomes of treatment with these 2 oral regimens. Patients and Methods: Records of patients with stage III colon cancer who underwent curative surgery and adjuvant chemotherapy from April 2007 and September 2014 were retrospectively reviewed. Results: A total of 258 patients with stage III colon cancer received oral adjuvant chemotherapy with UFT/LV (n ¼ 157, 61%) and CAPE (n ¼ 101, 39%). The overall rate of completion of scheduled treatment was 78.6%. Significantly fewer patients on UFT/LV completed the regimen compared with those on CAPE (117, 74.5% vs. 86, 85.1%; P < .01). There were no significant differences in oncologic outcome between UFT/LV and CAPE in terms of 3-year overall survival rates (OS; 95.8% vs. 92.4%, P ¼ .45) and 3-year relapse-free survival rates (RFS; 82.7% vs. 79.3%, P ¼ .8). Conclusion: The 3-year RFS and OS were similar for both regimens, yielding an excellent outcome. The selection of adjuvant chemotherapeutic regimens must be based on the patient's status as well as considering the incidences of adverse events, medical cost, and administration convenience.
Introduction
Adjuvant chemotherapy for patients with stage III colon cancer has been widely recommended since the early 1990s as standard treatment to improve overall survival (OS) and relapse-free survival (RFS). 1, 2 The National Surgical Adjuvant Breast and Bowel Project (NSABP) reported the results of a clinical trial that indicated significantly prolonged disease-free survival (DFS) and OS in patients with stage II and III colon cancer who received fluorouracil (5-FU) plus leucovorin (LV) (protocol C-03) compared with those who received semustine, vincristine, and 5-FU (protocol C-04). [3] [4] [5] NSABP protocol C-06 demonstrated that an oral regimen of uracil and tegafur (UFT) plus leucovorin (LV) was associated with DFS and OS similar to those obtained with a regimen of a weekly intravenous bolus of 5-FU/LV (5-year DFS 67.0% vs. 68.2%, 5-year OS 78.5% vs. 78.7%). [6] [7] [8] Pooling data from more than 3000 patients showed that adjuvant 5-FU significantly improves DFS and OS over surgery alone, with relative risk reductions of 30% and 26%, respectively. 9 The efficacy and tolerability of oral capecitabine (CAPE) was compared with 5-FU/LV by intravenous bolus for patients with stage III colon cancer in the adjuvant colon cancer therapy trial. 10 , and oral UFT/LV or CAPE. In Japan, given the expected benefits and possible risks of toxicity, a consensus has not been reached as to whether adjuvant regimens containing oxaliplatin should be administered for stage III colon cancer.
As noted previously, several major trials of treatment for stage III colon cancer have included oral adjuvant chemotherapy regimens as well as parenteral agents. The oral route is attractive because of its convenience. Although oral drugs derived from 5-FU derivatives have been compared with each other, 12 UFT/LV and CAPE have not been directly compared. This study aimed to evaluate the oncologic outcomes of these 2 oral adjuvant chemotherapy regimens.
Patients and Methods

Patient Selection
A search of the colorectal cancer database at Saitama Medical University International Medical Center yielded 316 patients with stage III colon cancer seen between April 2007 and September 2014 who underwent curative surgery and treatment with adjuvant chemotherapy. We excluded 22 patients who were treated with oxaliplatin-containing regimens and another 36 treated with oral fluoropyrimidine (S-1 Taiho Pharmaceutical Co, Ltd, Tokyo, Japan). This left 258 patients, treated with either UFT/LV (n ¼ 157) or CAPE (n ¼ 101). The database contained detailed information on patient characteristics, operative findings, histology, laboratory results, and adjuvant chemotherapy. Cancer was staged using the American Joint Committee on Cancer 7th edition classification for cancer of the colon and rectum. 13 All patients participating in this study provided informed consent. Access to patient records was granted by the hospital. This study was approved by the institutional review board of the Saitama Medical University International Medical Center.
Adjuvant Chemotherapy Regimens
The choice of adjuvant chemotherapy was made by the patient in consultation with the surgeon. Principles and chemotherapy regimens conformed to NCCN guidelines. All patients started receiving adjuvant chemotherapy at least 8 weeks after curative surgery. They were required to have an Eastern Cooperative Oncology Group performance status of 0 to 2, to have signed informed consent for the therapy, and to be aged between 20 and 80 years. Patients were informed about the scheduling of treatment, the costs, and the possible adverse effects.
UFT was a preparation of tegafureuracil in a molar ratio of 1:4. Tegafur (UFT Taiho Pharmaceutical Co, Ltd, Tokyo, Japan) is an oral fluorouracil prodrug converted to 5-FU in the liver. LV was used to modulate 5-FU biochemically, and has been widely adopted for the treatment of advanced colorectal cancer. 8, 14 Chemotherapy was given in 5-week cycles consisting of 4 weeks of oral UFT/LV and 1 week of rest. The cycles were repeated at least 5 times. The UFT dose was 300 mg/m 2 per day and LV dose 75 mg per day, divided into 3 doses administered every 8 hours with water. Patients were instructed to avoid food 1 hour before and after each dose. CAPE is an oral fluorouracil prodrug that generates 5-FU preferentially in tumor tissue through a 3-step enzymatic cascade (Xeloda Chugai Pharmaceutical Co, Ltd, Tokyo, Japan). 15 CAPE was administered at a dose of 1250 mg/m 2 twice a day for 14 days, followed by 7 days of rest. Standard care included a total of 8 cycles.
The amount of drug received was based on reported pill counts and patient declarations at the end of each cycle.
Patients were considered to have completed treatment if they took 80% or more of the scheduled total dose. The definition of discontinued treatment was the patients except the complete treatment. Toxicity was graded according to common toxicity criteria for adverse events.
Follow-Up Protocol
Patients were scheduled for follow-up visits every 3 months during the first 3 years, every 6 months for the next 2 years, and annually thereafter. Each visit included a physical examination and computed tomography (CT) of the chest, abdomen, and pelvis. Colonoscopy was performed during the first, third, and fifth year of follow-up.
Data Analysis
Statistical analysis was performed using SPSS version 21.0 software (SPSS Inc, Chicago, IL). The c 2 , t-test, or Mann-Whitney test was used as appropriate to compare the 2 regimens based on the distribution of the data as analyzed by the Shapiro-Wilk test. OS and RFS were calculated by the Kaplan-Meier method and compared by the log-rank test. P values were considered significant at < .05. This analysis was based on intention to treat.
Results
Patient Characteristics
The UFT/LV and CAPE groups were similar with respect to mean age, sex, depth of tumor invasion, tumor differentiation and lymphovascular invasion, and TNM stage (IIIA, IIIB, or IIIC) ( Table 1) . Lymph node (LN) dissection D3 (high ligation of the feeding artery) was carried out in 88% of patients and the median number of harvest LNs was 26 in 2 groups.
Adherence to Planned Total Dose
The overall rate of completion of the regimens was 78.6%, with 55 patients discontinuing the therapy without evidence of a Table 2 ).
Survival Analysis
The median follow-up was 48.5 months (range 14-84 months), and the UFT/LV group and the CAPE group were 48.8 months and 48 months, respectively. The oncologic outcomes did not differ significantly between UFT/LV and CAPE (3-year OS 95.8% vs. 92.4%, P ¼ .45, Figure 1 ; 3-year RFS 82.7% vs. 79.3%, P ¼ .8, Figure 2 ).
There were also no significant differences in RFS between patients who did or did not complete therapy in each of the 2 treatment groups. For those on UFT/LV, 3-year RFS was 83.8% in those who completed treatment versus 79.6% for those who discontinued it early (P ¼ .91, Figure 3A ). Results were similar in those on CAPE (80.5% vs. 85.1%, P ¼ .82, Figure 3B ).
Discussion
Several major prospective clinical trials for stage III colon cancer demonstrated superiority of adjuvant chemotherapy over surgery alone. Our previous retrospective study reported similar results in survival rate, and adjuvant chemotherapy identified as an independent predictor of reduction in cancer recurrence by multivariate analysis. 16 In our study with a median follow-up of 48.5 months, the 3-year RFS and OS were similar for both UFT/LV and CAPE, which can be considered excellent outcomes in stage III colon cancer. Although significantly more patients in our series completed 
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Clinical Colorectal Cancer September 2017 -e143 treatment with CAPE than those with UFT/LV, treatment completion did not affect either OS or RFS. It was suggested that the dose modifications, dose reduction, or discontinued drugs did not affect the therapy effect. One result from the X-ACT trial, the dose modifications did not influence the efficacy of CAPE. 17 Our study showed excellent survival rates, superior to those in previous studies. 9 The reason for the excellent clinical outcomes in our study is unclear, although several points should be considered.
The most important may be the surgical procedure used at our institution for D2/D3 LN dissection, perhaps leading to the eradication of potential residual tumor cells. Second, postoperative follow-up was performed frequently in this study, enhancing the chance of CT to detect recurrence in an earlier phase, which may facilitate surgical resection with curative intent. 18 Important issues for patients requiring adjuvant chemotherapy include the cost of treatment and the risk of adverse events. CAPE has several potential advantages over UFT/LV. The cost in Japan for 6 months of CAPE is half that of UFT/LV. Given the similar results for 3-year RFS and a 3-year OS, the lower cost of CAPE may be welcomed by patients. Also, many physicians think that patients regard the complex UFT/LV medication schedule (every 8 hours, avoiding meals 1 hour before or after the dose) as an obstacle. The simpler CAPE medication schedule (twice daily after meals) may be preferable. On the other hand, UFT/LV may be more convenient to administer than CAPE. Patients do not have to go to the hospital as often over 6 months for the 5-week cycles of UFT/LV, compared with the 3-week cycles of CAPE. Cost-effectiveness analysis should be conducted to take such factors into account. A major drawback of CAPE is the high incidence of hand-foot syndrome, which often interferes with the patient's daily life. The X-ACT trial found that 60% of patients treated with CAPE experienced hand-foot syndrome, 17% having grade 3 symptoms. 11 Our results were similar, with 72% of patients on CAPE experiencing hand-foot syndrome, and 22% of the group having grade 3 symptoms. In this respect, UFT/LV had an advantage over CAPE. Also, it was caused by the wide tolerance level of the treatment dosage that the completion rate of CAPE was high (85.1%). However, gastrointestinal toxicity (diarrhea, nausea, and vomiting) was more incident in UFT/LV, which often required admission with the incidence of hematological toxicity. Patients frequently visited the outpatient center and decided to discontinue treatment by patient's request. Adverse events are frequent and mild in CAPE, and rare and severe in UFT/LV. Consequently, more patients could not complete treatment with UFT/LV. The limitations of this study are its retrospective design, such that patients were not randomized and data collection was dependent on the information available in patient files. Therefore, selection bias cannot be ruled out, even though patients on the 2 regimens had similar clinical and pathologic characteristics. Treatment decisions were based on each patient's clinical situation. The aim of this study was to demonstrate an advantageous regimen for stage III colon cancer in a typical clinical setting. The study may have been underpowered to detect true differences because of its relatively small sample size; however, we did analyze a relatively large number of patients with a rare subset of colon cancer treated at a single institution, which might better replicate typical clinical practice. As cancer treatment continues to evolve, it is unlikely that a prospective, head-to-head trial of the 2 commonly used regimens, UFT/LV and CAPE, will be performed. However, our study does provide further evidence of the benefit patients may receive with this standard of care.
Conclusion
Three-year RFS and OS were similar for both UFT/LV and CAPE, affording excellent outcomes with oral medications alone as adjuvant treatment for stage III colon cancer. Although significantly more patients completed the CAPE regimen, the outcomes in both groups were similar regardless of whether or not the patients completed the planned treatment schedule. Thus, the selection of adjuvant chemotherapy regimens should be individualized for each patient, taking into account the cost, convenience of administration, and risk of adverse events.
Clinical Practice Points
Adjuvant chemotherapy following curative resection of stage III colon cancer is known to improve oncologic outcomes to a greater extent than surgery alone. A number of different regimens have been investigated and shown to be effective. Both UFT/LV and CAPE have been used for this purpose. However, we have not found any studies that directly compare these 2 regimens for adjuvant therapy after curative resection of stage III disease. We retrospectively reviewed the records of 258 patients treated at our institution with one or the other oral regimen after surgery. We found no significant differences in 3-year RFS or 3-year OS for either regimen. The outcomes also did not differ regardless of whether patients completed the scheduled total treatment dose. Given the continuing advances in chemotherapy for colon cancer, it is unlikely that these 2 agents will be compared in a headto-head trial because they are already accepted among the many alternatives for adjuvant treatment of stage III colon cancer. Although collected retrospectively, our results provide confirmatory evidence that both these regimens are good choices for adjuvant therapy. Treatment decisions can thus focus on other issues, such as cost, convenience, and potential adverse effects.
